信达生物打响“升级战”

药智网
Jul 01, 2025

近日,国内创新药龙头公司信达生物火力全开,频传喜讯。6月27日,信达生物减重创新药玛仕度肽获得NMPA批准上市,成为全球首个GCG/GLP-1双受体激动减重药物。6月28日,信达生物举办了研发日投资者交流会,其新一代IO和新一代ADC管线蓄势待发,PD-1/IL-2α-bias双抗融合蛋白IBI363有望成为下一个PD-1级肿瘤免疫爆款产品。肿瘤和综合管线齐发力,信达生物迈向高速增长新阶段。俞德超...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10